November 3, 2021 7:59am
Ain’t feelin’ all that nice, roll the dice
Earnings: Solid Biosciences (SLDB), Ionis Pharmaceuticals (IONS)
Pre-open indications: 8 SELLs, 4 BUYs with 1 Pump (or No Promote)
What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
Remember that overnight and pre-open actions in futures doesn't necessarily translate into actual trading in the coming day’s session.
Dow futures are DOWN -0.12% (-44 points), S&P futures are DOWN -0.06% (-3 points) and NASDAQ futures are UP +0.10% (+16 point)
U.S. stock futures were mixed, slipping as the Nasdaq slightly moves the needle in morning trading Wednesday as investors awaited a decision from the Fed,
European stocks were soft,
Asia-Pacific stocks were also mixed looking for clues on tapering.
Economic data docket: The Fed is expected to announce an end to its bond-buying program at the conclusion of its two-day meeting with possible clues on when the central bank plans to raise interest rates. Weekly mortgage applications and ADP payrolls data are also scheduled to be released.
Henry’omics:
All three major averages closed at records for the third session in a row. The small cap Russell 2000 rose slightly and closed at an all-time high.
The Fed concludes its two-day policy meeting at 2:30 p.m. with an announcement. Fed policymakers are widely expected to announce a decision to scale back asset purchases. The actual Fed taper would kick in at year-end. Analysts are expecting the central bank to reduce the $120 billion in monthly purchases — $80 billion in monthly Treasury purchases and $40 billion in government-backed mortgage securities — to zero by mid-2022. After that, Fed rate hikes could be on the table. <IBD)
Note: House Speaker Nancy Pelosi said the latest version of the reconciliation bill and bipartisan infrastructure package legislation also will include prescription drug price controls, a possible blow to pharma and biotech.
If you didn’t remember what happen at Tuesday night’s close and the quarter’s “number’s” impact, you won’t be prepared for today’s session:
Tuesday’s evening’s recap: “you say what, I say why. The sector started with a big downslide and ultimately drives to a quirky upside while sentiment is slippery and lackluster with share pricing risk orientation.” … https://www.regmedinvestors.com/articles/12165
Q4: November, 2 positive close
- October, 8 positive and 13 negative closes
Companies in my headlights – It’s your decision; I provide an idea and context:
SELL with a Pump or no promote:
Biostage (BSTG) closed down -$0.10 to $3.00 with 200 shares traded following Monday’s flat again with 80 shares traded and Friday’s flat with 95 shares traded.
- What’s there to invest in – the “Sword of Damocles” hanging over its recent insurance company rejection of legal expense/costs of a terminal death suit against the company?
- For a company with NO clinical trial, an a one (1) and a half year approved IND, four (4) employees and NO CRO <clinical research organization> initiation.
Probabilities versus share pricing indication moves:
SELL:
CRISPR Therapeutics (CRSP) – down -$0.19 or -0.20%,
Ionis Pharmaceuticals (IONS) – earnings down -$0.87 or -2.64%
Fate Therapeutics (FATE) -$0.01 or -0.02%,
Global Blood Therapeutics (GBT) -$0.36 or -0.92%,
Regenxbio (RGNX) -$3.59 or -9.81%,
Solid Biosciences (SLDB) -earnings
Sage Therapeutics (SAGE) post earnings -$0.82 or -1.88%,
Verastem (VSTM) -$0.02 or -0.72%
BUY:
Precigen (PGEN) +$0.06 or +1.15%,
bluebird bio (BLUE) -$1.15 or -4.62%,
Sangamo Therapeutics (SGMO), +$0.08 or +0.91%,
Voyager therapeutics (VYGR) +$0.05 or +1.29%
The BOTTOM LINE: Tuesday, the market rally continued its steady ascent as the Nasdaq climbed 0.3% with the small-cap Russell 2000 edging up 0.2%.
Two (2) more earnings on Wednesday ...
We are seeing to date, seven (7) net losses <uniQure (QURE), Alnylam Pharmaceuticals (ALNY), Regenxbio (RGNX), Sage Therapeutics SAGE), Ultragenyx Pharmaceuticals (RARE), MiMedx (MDXG) and Voyager therapeutics (VYGR)> earning’s releases that initiated Q3 earnings reporting season and beginning the tug-of-war between share pricing that is softer than usual and the usual LPS (loss-per-share) to be less than estimates and expectations.
It's highly risky to buy a stock just before earnings, and investors may want to take whole or partial profits on holdings with tiny gains.
The stem, cell and gene therapy earnings with Sangamo Therapeutics (SGMO) and Intellia Therapeutics (NTLA), Caladrius Biosciences (CLBS) on 11/4, Cellectis SA (CLLS) on 11/5, Editas Medicine (EDIT) on 11/8, Applied Genetic technologies (AGTC), Vericel (VCEL) on 11/9, Athersys (ATHX) and Brainstorm Cell Therapeutics (BCLI) coming 11/15 (to date).
I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”
RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
